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Objectives: Resistance to pyrimethamine in Plasmodium falciparum is conferred by mutations in the
gene encoding dihydrofolate reductase (DHFR). It is known that DHFR double mutants have evolved
independently in multiple geographic areas, whereas the triple mutant prevalent in Africa appears to
have originated in south-east Asia. In this study, we investigated whether other triple mutants may
have evolved independently in Africa.
Methods: We determined the DHFR genotypes and haplotypes of ﬁve microsatellite loci ﬂanking the
DHFR locus between 4.49 kb upstream and 1.48 kb downstream of 159 isolates collected from three
African countries (Republic of Congo, Ghana and Kenya).
Results: The CIRNI type of DHFR triple mutant (with mutations underlined at amino acid positions 51,
59 and 108) was predominant in the Republic of Congo (82%) and Ghana (81%) and was the second
most prevalent in Kenya (27%), where the CICNI type of DHFR double mutant was dominant. Three
distinct microsatellite haplotypes were identiﬁed in the DHFR triple mutant. One haplotype was
identical to that originating in south-east Asia. The other two haplotypes occurred in Ghana and
Kenya, which were unique, previously undescribed and identical to those of the two DHFR double
mutants found in the same locations.
Conclusions: This study presents strong evidence for the unique, multiple independent evolution of
pyrimethamine resistance in Africa. Indigenous evolution of the triple mutant from the double mutant
appears to have occurred in a step-wise manner in Kenya and Ghana or in nearby countries in east
and west Africa.
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The spread of Plasmodium falciparum resistance to commonly
used antimalarial drugs is a major public health problem in
malaria-endemic regions. The antifolate drug pyrimethamine/sulfa-
doxine inhibits two enzymes in the parasite’s folate synthesis
pathway. Amino acid changes at positions 50, 51, 59, 108 and 164
in one of these enzymes, dihydrofolate reductase (DHFR), are
strongly associated with pyrimethamine resistance.
1,2 At present,
isolates harbouring four mutations (CIRNL, with mutated amino
acids underlined) show the highest degree of resistance to pyri-
methamine. There are several DHFR genotypes in malaria-endemic
regions,
3 but the number of times the resistant genotype has
emerged in independent parasite lineages is thought to be consider-
ably limited.
4–7 In south-east Asia, an analysis of microsatellite
markers ﬂanking DHFR indicated that all resistant parasites
bearing two or more mutations share a single lineage.
4 In contrast,
in Africa, multiple indigenous lineages have been reported for
DHFR double mutants.
5,8 Nevertheless, it is currently accepted that
these indigenous double mutants have not yet produced a triple
mutant. Rather, nearly all lineages showing the DHFR triple
mutant found in Africa have been ascribed to the migration
of triple-mutant parasites from south-east Asia.
6–8However, given
the occurrence of multiple lineages of DHFR double mutants
in Africa, it is likely that triple mutants may have evolved indepen-
dently within the continent. In this study, we determined
the DHFR genotype and ﬂanking microsatellite haplotypes of
P. falciparum isolates from the Republic of Congo, Ghana and
Kenya. We discovered two previously undescribed lineages of the
DHFR triple mutant, from Ghana and Kenya, showing the indepen-
dent evolution of DHFR triple mutants within Africa.
Materials and methods
Study site and patients
Blood samples were collected from symptomatic individuals from
Pointe-Noire, Brazzaville and Gamboma in the Republic of Congo
in 2006 and from asymptomatic individuals at three villages near
Winneba in Ghana in 2004 and at two villages in Kisii District in
Kenya in 1998. In all regions, surveys were necessarily conducted
prior to the ofﬁcial introduction of pyrimethamine/sulfadoxine treat-
ment for malaria and so were not feasible with current populations.
These studies were approved by the administrative authority of the
Ministry for Research and Ministry for Health in the Republic of
Congo, the Ministry of Health/Ghana Health Service and the
Ministries of Health and Education in Kenya. In all surveys, each
patient was informed about the study prior to sampling, consent was
obtained (in the case of children, parents/guardians gave informed
consent) and medical follow-up was provided if needed.
DHFR genotyping and microsatellite haplotyping
Parasite DNA was puriﬁed using a QIAamp DNA Blood Mini Kit
(QIAGEN, Hilden, Germany) for samples from Ghana and Kenya
and the EZ1 BioRobotTM (QIAGEN) for samples from the Republic
of Congo. The ﬁrst 184 codons of DHFR, encompassing all known
polymorphic loci were ampliﬁed by nested PCR. Ampliﬁed products
were directly sequenced with a BigDye terminator v1.1 cycle sequen-
cing kit in an ABI 377 DNA Sequencer (Applied Biosystems, CA,
USA) as described previously.
9 In order to determine the evolutionary
history of pyrimethamine-resistant DHFR genotypes, we identiﬁed
individual haplotypes based on the association of ﬁve microsatellite
markers closely linked to the gene (0.1, 3.87 and 4.49 kb upstream,
and 0.52 and 1.48 kb downstream of DHFR).
4 Brieﬂy, variation in
the number of TA repeats in microsatellite loci was measured by
semi-nested PCR using ﬂuorescent end-labelled primers, followed by
electrophoresis on an ABI 377 sequencer and analysed with the
Genescan software (Applied Biosystems).
The microsatellite haplotype observed in south-east Asia, harbour-
ing an association of 200-194-176-106-203 bp at microsatellite loci
4.49, 3.87 and 0.1 kb upstream and 0.52 and 1.48 kb downstream of
DHFR was designated the SEA haplotype.
10 Microsatellite haplotypes
unique to the Republic of Congo, Ghana and Kenya are described in
the Results section. Haplotypes showing minor variations at one or
two loci were included in the respective major haplotypes.
Isolates showing mixed DHFR genotypes were excluded from
the analysis. Samples with more than one allele detected at any
microsatellite locus were also considered as mixed allele infections
and excluded. By these criteria, 131 (45%) of 290 samples were
excluded from the analysis.
Results
DHFR genotypes
We identiﬁed ﬁve distinct DHFR genotypes in 159 isolates: one
triple mutant (CIRNI), two forms of double mutant (CICNI and
CNRNI), one single mutant (CNCNI) and the wild-type
(CNCSI) (Figure 1). The triple mutant was found in all three
African countries with high prevalence in the Republic of
Congo and Ghana (81–82%), whereas the two double mutants
were distributed differently, the CICNI type in the Republic of
Congo and Kenya and the CNRNI type in Ghana.
Microsatellite haplotypes
DHFR double-mutant isolates carried microsatellite haplotypes
that were unique to each country (Figure 2a). In Kenya, the
majority of isolates were of a microsatellite haplotype consisting
Republic of Congo (n = 50)
Kenya (n = 55)
CNCSI
CNCNI
CNRNI
CICNI
CIRNI
Ghana (n = 54)
dhfr genotype a
Figure 1. Frequency of DHFR genotypes in P. falciparum isolates from
Kenya, the Republic of Congo and Ghana.
aGenotype is expressed as an
association of amino acids at positions 50, 51, 59, 108 and 164. Underlined
amino acids indicate mutated residues.
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253of an association of 204-190-156-96-203 bp (KEN haplotype), and
the rest had minor variations from the predominant haplotype.
Similarly, all isolates from the Republic of Congo were of one
predominant haplotype (198-194-170-98-197 bp; CON haplotype),
as were those from Ghana (198-204-168-104-205 bp; GHA haplo-
type). No SEA haplotype was observed.
We identiﬁed three microsatellite haplotypes associated with
the DHFR triple mutant (Figure 2b). In Kenya, both the KEN
haplotype and SEA haplotype were observed. Chimeric haplo-
types between the SEA and KEN haplotypes were observed,
probably generated by recombination between the two haplo-
types. In the Republic of Congo, the SEA haplotype was the
most prevalent (93%) and the KEN haplotype was also found at
low prevalence (7%). All three samples of the KEN haplotype
were chimeric haplotypes, having alleles of the SEA haplotype
at two loci. In Ghana, the SEA haplotype was most dominant
(70%), followed by the GHA haplotype (27%) and the KEN
haplotype (3%). Overall, among the three DHFR triple-mutant
lineages, the SEA haplotype was the most prevalent (75%), and
the prevalence of the KEN (13%) and GHA (12%) haplotypes
was low but signiﬁcant.
Discussion
The present study clearly shows that there are three lineages of the
CIRNI pyrimethamine-resistant DHFR triple mutant in the
Republic of Congo, Ghana and Kenya. One of the three lineages
(a)
Haplotype n y r t n u o C
–4.49 kb –3.87 kb –0.1 kb 0.52 kb 1.48 kb
Kenya 204 190 156 96 203 33
(CICNI)
(CICNI)
196 190 156 96 203 2
208 190 156 96 203 1
204 190 156 96 211 1
202 186 156 96 203 1
Republic of Congo 198 194 170 98 197 5
206 194 170 98 197 1
198 190 170 96 197 1
Ghana 198 204 168 104 205 8
(CNRNI) 202 186 168 104 205 1
Haplotype n y r t n u o C
–4.49 kb –3.87 kb –0.1 kb 0.52 kb 1.48 kb
200 194 176 106 203 4
204 194 176 106 203 1
204 190 176 106 203 1
200 190 156 96 203 2
204 190 156 96 203 7
200 194 176 106 203 36
202 194 176 106 203 1
200 194 176 106 197 1
204 194 176 96 203 1
200 194 156 96 203 2
200 194 176 106 203 29
198 194 176 106 203 1
200 194 176 106 205 1
200 206 168 104 205 1
202 186 168 104 205 2
198 204 168 104 205 9
204 190 156 96 203 1 KEN haplotype
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indicated position
Kenya
SEA haplotype
KEN haplotype
CON haplotype
GHA haplotype
Size of microsatellite markers (bp) at
indicated position
KEN haplotype
Figure 2. Microsatellite haplotypes in P. falciparum isolates having DHFR double (a) and triple (b) mutations in Kenya, the Republic of Congo and Ghana.
KEN haplotype, CON haplotype, GHA haplotype and SEA haplotype are unique associations at ﬁve microsatellite loci of alleles. Haplotypes showing minor
variations at one or two loci (unboxed) were included in the respective major haplotypes. These alleles are likely to be generated by a TA repeat mutation
and/or recombination events between unlike haplotypes. (b) A variant belonging to the SEA haplotype from the Republic of Congo had an allele at 1.48 kb
that was seen in the DHFR double mutant in the same country.
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254is identical to the SEA lineage and the other two lineages, the
KEN lineage and GHA lineage, are unique to Africa. The SEA
lineage was the most prevalent of the DHFR triple mutants, but
the prevalence of the two African lineages was signiﬁcant.
Importantly, microsatellite haplotypes of the two African lineages
were also found from parasites with DHFR double mutants, while
no double mutants shared the SEA microsatellite haplotype. These
ﬁndings present strong evidence for the indigenous evolution of
the DHFR triple mutant from the double mutant in Africa.
Previous reports have not identiﬁed indigenously generated
African triple DHFR mutants. These include two studies analysing
24 triple mutants from South Africa,
6 and 204 from 11 sub-
Saharan African countries.
7 In these countries, all triple mutants
except one showed an identical or very similar microsatellite hap-
lotype to the SEA haplotype. This suggests that the DHFR triple
mutant currently predominant in Africa was imported from SEA,
rather than indigenously generated. In the present study, the SEA
lineage was the most prevalent in all countries considered, but two
other indigenous lineages were also observed.
The co-prevalence of the SEA haplotype and the KEN/GHA
haplotypes in Africa suggests that the indigenous DHFR triple
mutant may have evolved earlier than or contemporaneously with
the migration of the SEA type from south-east Asia—an initial
triple mutant, either indigenously evolved or imported, would
quickly spread out through the continent, as observed in
south-east Asia, where only a single lineage of DHFR triple or
quadruple mutant is presently prevalent.
4,10 This scenario is based
on the assumption that pyrimethamine pressure was continuously
and extensively present. However, in Africa, the history of
pyrimethamine administration differs greatly country-by-country.
Indeed, we observed the DHFR wild-type, a single mutant and
double mutants in three African countries, a situation in sharp con-
trast to that in south-east Asia where all P. falciparum
populations show a single lineage of DHFR triple/quadruple
mutant.
4,10 Dispersal of drug resistance obviously depends on
many factors, including movements of infected people, the
intensity of malaria transmission, the level of host population
immunity and the history and extent of drug usage. Thus, the
strength of any selective sweep by pyrimethamine differs depen-
ding on area, making it difﬁcult to infer which occurred earlier;
the migration of the DHFR triple mutant from south-east Asia into
Africa or the indigenous evolution of the triple mutant in Africa.
This study also presents strong evidence for the indigenous evol-
ution of DHFR double mutants in Africa. All three countries
studied have a unique, country-speciﬁc lineage of a DHFR double
mutant, suggesting that the generation of DHFR double mutants is
not a rare event in Africa, a situation that differs from south-east
Asia and Melanesia, where the generation of double mutants has
been very rare.
10 As the prevalence of P. falciparum is much
greater in many parts of Africa than in most of south-east Asia and
Melanesia, the pool of potential drug-resistant mutant parasites
available for selection by drug pressure is much larger. We believe
that this situation may explain the generation and selection of mul-
tiple independently originating drug-resistant mutants in Africa.
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